Abstract | BACKGROUND: OBJECTIVE: The aim of this study was to comprehensively review all available literature regarding the mechanism of action, pharmacokinetics, clinical efficacy, and adverse effects of aripiprazole. METHODS: Relevant data were collected using MEDLINE and International Pharmaceutical Abstracts searches with the terms aripiprazole and OPC-14597 and with no limitations on year. Abstracts and posters presented at national and international scientific meetings were also reviewed. RESULTS:
Aripiprazole exhibits linear pharmacokinetics and is administered once daily. In multiple clinical trials, aripiprazole was effective in significantly reducing symptomatology associated with schizophrenia-related disorders compared with placebo (P < 0.05). Dosages > or =15 mg/d more consistently produced significant reductions from baseline of Positive and Negative Syndrome Scale total scores (P < 0.05) and were more likely to elicit a response than smaller dosages. Effects observed were comparable to those seen with risperidone and haloperidol, which were also significantly more effective than placebo (P < or = 0.05). Aripiprazole exhibited a favorable safety and tolerability profile, with a low propensity to cause extrapyramidal symptoms, weight gain, cardiovascular abnormalities, hyperprolactinemia, hypercholesterolemia, or glucose dysregulation. CONCLUSIONS:
Aripiprazole represents a well-tolerated and effective addition to the antipsychotic armamentarium. However, definitive advantages associated with dopamine partial agonism have yet to be determined. Long-term, head-to-head comparisons with other SGAs are needed to establish the effects of chronic administration and the relative safety and efficacy of aripiprazole.
|
Authors | Anthony DeLeon, Nick C Patel, M Lynn Crismon |
Journal | Clinical therapeutics
(Clin Ther)
Vol. 26
Issue 5
Pg. 649-66
(May 2004)
ISSN: 0149-2918 [Print] United States |
PMID | 15220010
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., Review)
|
Chemical References |
- Antipsychotic Agents
- Piperazines
- Quinolones
- Aripiprazole
|
Topics |
- Antipsychotic Agents
(adverse effects, pharmacology, therapeutic use)
- Aripiprazole
- Bipolar Disorder
(drug therapy)
- Humans
- Piperazines
(adverse effects, pharmacology, therapeutic use)
- Psychiatric Status Rating Scales
- Psychotic Disorders
(drug therapy)
- Quinolones
(adverse effects, pharmacology, therapeutic use)
- Randomized Controlled Trials as Topic
- Schizophrenia
(drug therapy)
|